Cogstate Investor Briefing
Released
Released
Announcement PDF
ASX Announcement
22 August 2024
FY24 Results Investor Briefing
Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial results
for the year ended 30 June 2024 and also provides commentary in respect of the business and financial outlook.
The presentation material is attached to this announcement.
Investors are invited to join Cogstate CEO, Brad O’Connor for a live webcast of this presentation today, Thursday 22
August 2024, at 8:30am Australian eastern standard time.
Investors can register via the following weblink to join the live event or receive the recording if unable to attend:
https://attendee.gotowebinar.com/register/1561058463047040604
Additionally, a video recording of the presentation will be available later today at the Cogstate Investor Centre
homepage: https://www.cogstate.com/investors/
This announcement was authorised for release by the Board of Directors of Cogstate Ltd.
FY24 Investor Briefing | Page 1
About Cogstate
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the
development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable
and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome
assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s
clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches,
advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs
of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically
validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician
time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in the USA
& Asia. For more information, please visit www.cogstate.com.
For further information contact:
Brad O’Connor, Chief Executive Officer, boconnor@cogstate.com
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's
views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and
provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement nor any information
made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past,
present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”,
“guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking
statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking
statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and
contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors
that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general
guide only and should not be relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any
projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's
business strategies, including the that the results of any of those strategies will be realised in the period for which the forwardlooking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is
sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its
customers which are influenced by factors that are outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation,
none of Cogstate, its representatives or advisers assumes any obligation to update these forward-looking statements. No
representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking
statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or
regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide
any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future
events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are
also forward-looking statements.
FY24 Investor Briefing | Page 2
Investor Update
August 2024
© 2024 Cogstate Ltd. All rights reserved.
Disclaimer
This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general na ture and does not purport to
be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the
Corporations Act. This presentation may contain statements, opinions, projections, forecasts and other material (forward look ing statements), based on
various assumptions. Those assumptions may or may not prove to be correct. None of Cogstate, its respective officers, employe es, agents, advisers or
any other person named in this presentation makes any representation as to the accuracy or likelihood of fulfilment of any fo rward looking statements or
any of the assumptions upon which they are based.
The information contained in this presentation does not take into account the investment objectives, financial situation or p articular needs of any recipient
and is not financial product advice. Before making an investment decision, recipients of this presentation should consider th eir own needs and situation
and, if necessary, seek independent, professional advice.
To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty, repres entation or guarantee as to
the accuracy, completeness or reliability of the information contained in this presentation. Further, none of Cogstate and it s respective officers,
employees, agents and advisers accept, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in
connection with, the information contained in this presentation. Any recipient of this presentation should independently sati sfy themselves as to the
accuracy of all information contained herein.
2
1
Alzheimer’s disease R&D is progressing &
expanding in a predictable manner
2
Eisai renegotiation was commercially sound
AND provides important options for growth
3
Revenue growth is impressive in the context of
Clinical Trials sales
4
Technology investment over recent years has
created efficiency & margin improvement
Key Considerations
3
Alzheimer’s Disease
Market Expansion
1
Alzheimer’s disease R&D is progressing &
expanding in a predictable manner
2
Eisai renegotiation was commercially sound
AND provides important options for growth
3
Revenue growth is impressive in the context of
Clinical Trials sales
4
Technology investment over recent years has
created efficiency & margin improvement
• More pharma companies are investing in
Alzheimer’s R&D
Customer Growth
• Four pharma companies started phase 2
programs with Cogstate in FY24, three of
which were new customers
• Cogstate support of successful phase 3
program is important in winning new work
Changed Environment
• Phase 3 trials have been slower as pharma
execs wait to understand the market for newly
approved treatments, including regulatory
acceptance and barriers to adoption
• Lack of phase 3 Alzheimer’s trials reduced
Clinical Trials sales contracts executed in
FY24
4
Cogstate Alzheimer’s Trial Starts
Large Pharma Customers
Number of New Trials
8
7
Note 2
6
Growth in Alzheimer’s
Large Pharma Customers
5
4
3
2
Cogstate strategy is to engage sponsor teams at the
earlier stages of development and follow a therapy
through to later stages.
Note 1
1
0
FY21
FY22
Phase 1
FY23
Phase 2
FY24
Total contract value to Cogstate of one diseasemodifying Alzheimer’s program can be up to $80m
across phases 1 to 3.
Phase 3
FY21
FY22
FY23
FY24
Value of Alzheimer’s
contracts 3
$35.4m
$74.5m
$25.7m
$12.9m
Alzheimer’s as a % of
total contracts
75%
90%
75%
48%
Large Pharma as a %
of total Alzheimer’s
87%
80%
83%
100%
Due to the cost of these phase 3 programs, they are
usually only run by large Pharma.
Growth comes from securing early-stage
Alzheimer’s trials from large Pharma, which then
advance to phase 3
Note 1 : Trials suspende d b efo re patients recruited, sub seq uently reo rganised in early FY 25. Limited revenue impact in either FY23 or FY 24 fro m either contract.
Note 2 : Start-up agr eement o nly (low va lue, allo wing Cogstate to begin work). Full a greement execu ted ea rly FY25.
Note 3 : Value of co ntr acts e xecuted in any p eriod includes con tra cts for new tria ls as well as a me ndments to ongoing trials.
5
Value of Clinical Trials Sales Contracts
- Excluding Alzheimer’s Trials
16
60% Growth In Sales
Outside Of Alzheimer’s
US$ Millions
14
12
Other significant indications include:
10
•
Rare Diseases
8
•
Major Depressive Disorder
6
•
Migraine
4
•
Narcolepsy
2
•
Parkinson’s disease
•
Schizophrenia
0
FY21
FY22
FY23
FY24
6
IP Ownership
Financial Implications
• In FY20, licensed IP for $45m plus royalties
1
Alzheimer’s disease R&D is progressing &
expanding in a predictable manner
2
Eisai renegotiation was commercially sound
AND provides important options for growth
3
Revenue growth is impressive in the context of
Clinical Trials sales
4
Technology investment over recent years has
created efficiency & margin improvement
• In FY24, bought-back for $15m reduction in
future payments to Cogstate, impacting
cashflow from FY28-FY31 only
Eisai Continued Relationship
• Eisai continue to market Cogstate technology
to doctors in USA & community in Asia
Commercial Implications
• Under non-exclusive license, Cogstate has
regained IP ownership
• Roll-out of new Alzheimer’s therapies has
highlighted difficulties in US healthcare system
- suggesting a need for better and earlier
identification of impairment in the community
• Opportunity for Cogstate to identify patients for
both treatment and trials – opportunities that
were closed off to Cogstate without
amendment
7
Revenue Growth
Clinical Trials Sales
1
Alzheimer’s disease R&D is progressing &
expanding in a predictable manner
2
Eisai renegotiation was commercially sound
AND provides important options for growth
3
Revenue growth is impressive in the context of
Clinical Trials sales
4
Technology investment over recent years has
created efficiency & margin improvement
• $27m of clinical trials sales
• Sales drive in-period revenue growth,
especially growth in license fees
License Fee Revenue
• Usually recognised in year contract executed
• Historical analysis suggests license fees
usually 18%-20% of Clinical Trials revenue
• FY24 license fees 13% of Clinical Trials
revenue
Revenue Growth = Service Expansion
• 9% growth in FY24 Clinical Trials revenue,
despite low level of license fees, reflects
growing service offering by Cogstate
• Positioned well for improved revenue growth
when sales growth returns with associated
higher level of license fees
8
Technology Driving
Margin Improvement
1
Alzheimer’s disease R&D is progressing &
expanding in a predictable manner
2
Eisai renegotiation was commercially sound
AND provides important options for growth
3
Buy-back of IP from Eisai was a good financial
deal AND provides important options for growth
4
Technology investment over recent years has
created efficiency & margin improvement
Technology Investment
• Recent investment mainly focused on
automation in Cogstate service delivery
May-23 Staff Restructure
• As a result of efficiency gains, staff restructure
undertaken in May-23
• Predominantly impacting Clinical Trials group
Margin Improvement
• 6 points improvement in Clinical Trials gross
margin reflecting lower staff costs
• That is, $4.0m increase in gross margin from
$3.3m increase in revenue
• Bonus: Operating expenses also down 4% on
prior year
9
Strong Start to FY25
•
Net value of contracts executed FY25 year-to-date is $9.3m. The Net value includes:
o
Gross value of sales contracts executed since 01-Jul-24 (FY25 year-to-date) is $29.6m
o
Program of studies for a drug candidate was redesigned to consolidate multiple Phase 3 trials into a single larger trial
➢ Same customer, same drug, new protocol with larger total contract value
➢ The ongoing trials were suspended during FY24 and therefore did not meaningfully contribute revenue in FY24
➢ Larger trial commenced in Jun-24 quarter under start-up agreement – therefore revenue now generating
o
Reconciliation of completed phase 3 program where $4.1m of budget was not used and therefore has been removed from
contracted future revenue
•
Contracted future revenue has been adjusted to provide for both the new contracts as well as the reorganisation of older contracts.
•
As such, contracted future Clinical Trials revenue at 21-Aug-24 is $95.0m, of which $31.4m is expected to be recognised in FY25
As at 21-Aug-24
As at 30-Jun-24
As at 30-Jun-23
Contracted Clinical Trials revenue expected to be recognised in coming financial year
US$31.4m
US$26.8m
US$27.7m
Contracted Healthcare revenue expected to be recognised in coming financial year
US$2.2m
US$2.2m
US$4.2m
Total contracted revenue expected to be recognised in coming financial year
US$33.6m
US$29.0m
US$31.9m
10
FY24 Financial Results
11
FY24 Financial Results
(All figures in US$, unless stated)
Clinical sales contracts executed
$27.0m
Doesn’t tell the full story.
Alzheimer’s growth profile for future periods.
Contracted future revenue as at 21 August 2024
-21%
Lower level of Clinical Trial sales contracts.
Healthcare: Eisai amendment negative impact.
+7%
Clinical Trials revenue growth
Healthcare down due to Eisai contract amendment
Up from PCP of $0.7m
Growth in Clinical Trials.
$7.1m
Revenue growth.
Cost control incl. restructure undertaken May-2023.
+135%
Net Cash Balance at 30 June
Operating net cash flow
$5.8m
-16%
Profit before Tax
Group Revenue
$43.4m
$110.9m
+784%
$29.4m
Up from PCP of $27.8m
A$5.5m spent on share buyback during FY24.
+6%
12
Cogstate Group
US$ millions
FY24
FY23
YTY %
Revenue
43.4
40.5
7%
Gross Profit
24.6
20.8
18%
GP%
57%
52%
5% Pts
Operating Expense
(15.3)
(16.0)
(4%)
Depreciation & Amortization
(2.7)
(2.6)
6%
EBIT
6.5
2.2
196%
15%
5%
10% Pts
Other Income/(Expenses)
0.6
0.8
(29%)
Net Profit before Tax
7.1
3.0
135%
EBIT%
Highlights
•
Revenue growth resulting from Clinical
Trials, offset by decline in Healthcare
•
Strong improvement in gross profit margin
resulting from May 2023 restructuring
actions and cost management
•
EBITDA and EBIT margins improving but
not yet at target model
•
Strong growth in Profit before Tax
13
Segments
Highlights
Clinical Trials (including Research)
Clinical Trials
US$ millions
FY24
FY23
YTY %
Revenue
39.4
36.1
9%
Direct Costs (excluding depreciation)
(13.5)
(14.0)
3%
SG&A
(4.2)
(4.3)
3%
Gross Contribution
21.7
17.7
23%
55%
49%
6% Pts
GP%
•
Growth in revenue despite low in-year
revenue yield due to low new contract
sales
•
Strong improvement in gross profit
margin with benefit from May 2023
restructuring actions, cost management,
partially offset by lower than historical
average SW license mix
Healthcare
•
Decline in revenue a result of
renegotiated global licensing agreement.
•
Improving margin resulting from cost
benefits from May 2023 restructuring
actions, offset by investment in go-tomarket strategy development.
Healthcare
Revenue
4.0
4.4
(9%)
Direct Costs
(1.1)
(1.3)
14%
Gross Contribution
2.9
3.1
(8%)
72%
71%
1% Pts
GP%
14
Cash Flow
US$ millions
FY24
FY23
YTY %
Net Profit after Tax
5.4
3.6
53%
Depreciation & Amortization
2.5
2.1
18%
Disposal of Assets
0.1
0.4
(118%)
Non-cash employee benefits
0.8
1.6
(53%)
Grant funding received
(0.3)
(0.3)
(12%)
Exchange Rate differences
(0.5)
(0.1)
461%
Change in working capital
(2.2)
(6.6)
(67%)
Operating Cash Flow
5.8
0.7
784%
Cash Flow used in investing activities
(1.1)
(1.7)
(34%)
Cash flow used in Financing activities
(3.2)
(0.9)
260%
Total Cash Flow
1.5
(1.9)
175%
Highlights
•
Increased receipts from customers from
growth in Clinical Trials
•
Reduced employee costs following
May-23 restructure
•
Lower cash flow used in Investment
activities results from lower
capitalisation of labour costs
•
Higher cash flow used in Financing
activities due to share buy-back
program : US$3.6m (A$5.5m)
•
US$29.4 million net cash
15
Future Contracted Revenue Run-Off
Analysis
40
• FY25 revenue under contract, $33.6m as at
21-Aug-24
35
➢ Clinical Trials is $31.4m, compared to
$27.7m at 30-Jun-23, up 13% YTY
30
➢ Healthcare is $2.2m, compared to $4.2m
at 30-Jun-23, reflecting to renegotiation
to the Eisai global licensing agreement.
25
• Expected recognition of Clinical trials revenue
reflects reorganisation of large trials, with more
revenue in outer years
20
15
Clinical Trials
Revenue At
21-Aug-24
US$m
Clinical Trials
Revenue At
30-Jun-23
US$m
FY25
$31.4
$30.3
FY26
$21.3
$18.2
FY27
$15.1
$11.4
FY28
$11.1
$8.3
FY29+
$16.1
$2.0
10
5
0
FY25
FY26
FY27
Clinical Trials
FY28
FY29+
Healthcare
Clinical Trials revenue backlog $95.0m at 21-Aug-24 vs $98.0m at 30-Jun-23
16
Business Updates
17
Central Nervous System diseases is a large and growing
area of drug development with few strong competitors
CNS is the second
largest segment of the
$25B clinical trials
market, taking 18%
second to oncology.
Source: https://shorturl.at/eqmKE
18
Alzheimer’s disease is expected to be the fastest
growing indication in CNS
12% - 14% CAGR
19
Alzheimer’s disease is expected to be the fastest
growing indication in CNS
•
First-gen early-stage AD drugs are on market – prescription rates
are slower than expected but improving
•
Health system preparedness is happening and Cogstate has
ambitions to play a role here
•
New dosage forms are coming
•
Label expansions for pre-symptomatic AD trials are well into
phase 3 – where Cogstate has 100% market share
•
This is fueling growth of Alzheimer’s R&D investment, much like MS
30 years ago
•
Alzheimer’s trials are long to recruit and expensive to run; and we
believe that, with technology, we can help improve speed and data
quality at lower costs
20
Cogstate Focus
Areas Next 12 Months
21
End-to-End Solution
for Optimized CNS
Endpoints
One the challenges with CNS trials is
they depend on clinical outcome
assessments that are prone to error
and variance, which can diminish their
sensitivity to drug effect. Cogstate
brings a uniquely comprehensive set of
technologies and solutions to address
this challenge from every angle.
22
Cogstate Opportunity
Outside Clinical Trials
23
Re-Acquired IP
Based on our assessment of the opportunity,
Cogstate has re-negotiated its agreement with
Eisai and re-acquired rights to Cogstate IP.
Eisai now has non-exclusive license of:
• Cognigram in USA; and
• CogMate in certain Asian countries.
Cognigram is FDA cleared medical device for physician use.
Eisai will promote to USA based clinicians, with focus on
Annual Wellness Visit available to all medicare recipients.
CogMate is a direct-to-consumer assessment, based on the
Cogstate Brief Battery (same tests as Cognigram).
Cogstate will still receive a further $11.5m of future
guaranteed royalties under the amended agreement.
24
FY25 Outlook
Encouraging start to FY25
• $9.3m net sales contracts
• $29.6m gross sales contracts
Significant market opportunity in CNS diseases
Opportunities for sales growth in Alzheimer’s
disease and other indications
Opportunities for exciting pilot programs outside
of clinical trials with IP re-secured
Expect to grow revenue & profit in FY25
• No specific guidance provided, pending
execution of sales contracts
Share buy-back has been suspended until further
notice
25
Appendices
27
Cogstate Offering
In Clinical Trials
28
Cogstate brings together
clinical science
expertise, innovative
technology, and
operational excellence
to help clinical trial teams
understand drug safety
and efficacy.
29
Strategic guidance on the selection, execution
and analysis of cognitive measures.
•
Access to thousands of cognitive data profiles
generated in different study populations,
interventions, mechanisms
•
Endpoint selection, powering decisions,
robust statistical analysis and interpretation of
study results supportive of product efficacy,
safety and differentiating claims
30
Licensing and translating rating scale instruments
for a study is a meticulous process that can
dramatically impact trial start-up timelines and
data quality.
•
Licensing agreements, translations and
linguistic validation, development of master
source documents
•
Migration to electronic formats (eCOA)
•
Logistics management of printed source,
hardware, manipulatives and instructions
31
At-home data collection is increasing in Clinical
Trials. Cogstate is expertly positioned to support
remote administration of conventional clinical
assessments as well as Cogstate proprietary
digital assessments.
•
•
Self-administered digital assessments
Central rating via telehealth
32
Clinical trial sponsors must ensure raters
administer scales in the most accurate and
standardized way possible.
•
Prepare raters to administer scales to high
standards in the timeliest way possible.
•
Eliminate unnecessary training based on rater
experience and leverage customized
eLearning curriculum supportive of expedited
study start-up.
33
Conventional paper and pencil assessments
allow missing data and erroneous transcription.
Electronic clinical outcome assessments (eCOA)
allow for digital capture of study data with pre-set
workflows, real-time edit checks and algorithmic
flags to improve data quality.
•
Patient-reported, clinician-reported, care
partner-reported, performance-based
•
Partner relationships
34
Rater variability and error can be detrimental to a
study, adding noise and diminishing signal
detection.
•
Develop and execute strategic, risk-based
central monitoring programs to ensure the
reliability and validity of clinical measures.
•
250+ highly trained clinical and scientific
experts who provide in-language support in
40+ languages.
35
Increases the sensitivity and specificity of the
measurement of human cognition.
•
Designed and validated to assess memory,
verbal learning, attention, psychomotor
function, motor function, executive function,
vigilance, and emotional recognition
•
Batteries are customized for the unique aims
of each study -- used in hundreds of global
clinical trials for both pediatrics and adults.
36
Share your feedback
Discover